Online inquiry

IVTScrip™ mRNA-Anti-CD40, SGN-40(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ14777MR)

This product GTTS-WQ14777MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CD40 gene. The antibody can be applied in Multiple myeloma (MM), Non-Hodgkin's lymphoma (NHL) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001250.6
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 958
UniProt ID P25942
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD40, SGN-40(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ14777MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5228MR IVTScrip™ mRNA-Anti-Factor IX substitute, CB 2679d(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA CB 2679d
GTTS-WQ9541MR IVTScrip™ mRNA-Anti-TNFRSF17, J6M0(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA J6M0
GTTS-WQ6217MR IVTScrip™ mRNA-Anti-RABVgp4, CR4098(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CR4098
GTTS-WQ5496MR IVTScrip™ mRNA-Anti-IL6, CDP 6038(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CDP 6038
GTTS-WQ3460MR IVTScrip™ mRNA-Anti-S, AZD8895(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA AZD8895
GTTS-WQ13489MR IVTScrip™ mRNA-Anti-IgG-Fc, PRTX-100(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA PRTX-100
GTTS-WQ6565MR IVTScrip™ mRNA-Anti-EGFR, DC-1630423(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA DC-1630423
GTTS-WQ11593MR IVTScrip™ mRNA-Anti-ERBB2, MGAH-22(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA MGAH-22
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW